Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Core Viewpoint - Altimmune, Inc. is set to report its second quarter 2024 financial results on August 8, 2024, and will provide a business update during a conference call [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 8:30 am E.T. on August 8, 2024 [1] - The conference call will be accessible via a live webcast on Altimmune's Investor Relations website [1] - A replay of the conference call will be available on the Investor Relations website for up to three months after the event [1] Group 2: Company Overview - Altimmune is a clinical-stage biopharmaceutical company focused on developing next-generation peptide-based therapeutics [2] - The company is currently developing pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating obesity and MASH [2]